Showing results (2101-2110 of 3,032) with videos related to
Sort By:
Pageof 304
Transplantation|May 23, 2002
Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720Fumin Fu, Shiling Hu, Jeffrey Deleo, et al.The Plant Cell|November 1, 2018
S-Locus F-Box Proteins Are Solely Responsible for S-RNase-Based Self-Incompatibility of Petunia PollenLinhan Sun, Justin S Williams, Shu Li, et al.Frontiers in Behavioral Neuroscience|January 31, 2014
The neural correlates of risk propensity in males and females using resting-state fMRIYuan Zhou, Shu Li, John Dunn, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 20, 2016
Therapeutic Effects of Punicalagin Against Ovarian Carcinoma Cells in Association With β-Catenin Signaling InhibitionJian-Ming Tang, Jie Min, Bing-Shu Li, et al.International Journal of Pharmaceutics|May 4, 2020
The development and validation of a quality by design based process analytical tool for the inline quantification of Ramipril during hot-melt extrusionSuha M Dadou, Zoe Senta-Loys, Ammar Almajaan, et al.JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.Oncotarget|September 3, 2016
Metastatic lymph node ratio can further stratify risk for mortality in medullary thyroid cancer patients: A population-based analysisNing Qu, Rong-Liang Shi, Zhong-Wu Lu, et al.Cell Biology International|November 20, 2010
Co-transfection and tandem transfection of HEK293A cells for overexpression and RNAi experimentsZhen-Li Xie, Shu-Li Shao, Jian-Wei Lv, et al.Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trialAndrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.Pageof 304